Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 483238, 10 pages
http://dx.doi.org/10.1155/2015/483238
Research Article

Sex-Differences in Renal Expression of Selected Transporters and Transcription Factors in Lean and Obese Zucker Spontaneously Hypertensive Fatty Rats

1Institute for Cardiovascular Physiology (Physiology I), Faculty of Medicine, Goethe-University, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
2Cancer Research Institute, Slovak Academy of Sciences, Vlarska 7, 83391 Bratislava, Slovakia
3Institute for Systemic Physiology and Pathophysiology, University Medical Center Göttingen, Humboldtallee 23, 37073 Göttingen, Germany

Received 1 October 2014; Revised 22 December 2014; Accepted 23 December 2014

Academic Editor: Bernard Portha

Copyright © 2015 Andrea Babelova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Afkarian, M. C. Sachs, B. Kestenbaum et al., “Kidney disease and increased mortality risk in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 302–308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Philis-Tsimikas, “Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control,” The American Journal of Medicine, vol. 126, no. 9, pp. S21–S27, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. S. Fox, K. Matsushita, M. Woodward et al., “Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis,” The Lancet, vol. 380, no. 9854, pp. 1662–1673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. P. N. van Buren and R. Toto, “Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management,” Advances in Chronic Kidney Disease, vol. 18, no. 1, pp. 28–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Maranon and J. F. Reckelhoff, “Sex and gender differences in control of blood pressure,” Clinical Science, vol. 125, no. 7, pp. 311–318, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Maric, “Sex, diabetes and the kidney,” American Journal of Physiology—Renal Physiology, vol. 296, no. 4, pp. F680–F688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Anzai, Y. Kanai, and H. Endou, “Organic anion transporter family: current knowledge,” Journal of Pharmacological Sciences, vol. 100, no. 5, pp. 411–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Burckhardt, “Drug transport by Organic Anion Transporters (OATs),” Pharmacology and Therapeutics, vol. 136, no. 1, pp. 106–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Koepsell, “Polyspecific organic cation transporters and their biomedical relevance in kidney,” Current Opinion in Nephrology and Hypertension, vol. 22, no. 5, pp. 533–538, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Wang and D. H. Sweet, “Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease,” The AAPS Journal, vol. 15, no. 1, pp. 53–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Y. Chu, K. Bleasby, J. Yabut et al., “Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein,” Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 2, pp. 673–683, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-I. Asaka, T. Terada, M. Okuda, T. Katsura, and K.-I. Inui, “Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3,” Pharmaceutical Research, vol. 23, no. 4, pp. 697–704, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. N. Buist, N. J. Cherrington, S. Choudhuri, D. P. Hartley, and C. D. Klaassen, “Gender-specific and developmental influences on the expression of rat organic anion transporters,” The Journal of Pharmacology and Experimental Therapeutics, vol. 301, no. 1, pp. 145–151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. Giacomini and S.-M. Huang, “Transporters in drug development and clinical pharmacology,” Clinical Pharmacology and Therapeutics, vol. 94, no. 1, pp. 3–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Ogasawara, T. Terada, J.-I. Asaka, T. Katsura, and K.-I. Inui, “Hepatocyte nuclear factor-4α regulates the human organic anion transporter 1 gene in the kidney,” The American Journal of Physiology—Renal Physiology, vol. 292, no. 6, pp. F1819–F1826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Popowski, J. J. Eloranta, M. Saborowski, M. Fried, P. J. Meier, and G. A. Kullak-Ublick, “The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4α and suppressed by bile acids,” Molecular Pharmacology, vol. 67, no. 5, pp. 1629–1638, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Qadri, L. J. Hu, M. Iwahashi, S. Al-Zuabi, L. C. Quattrochi, and F. R. Simon, “Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2),” Toxicology and Applied Pharmacology, vol. 234, no. 3, pp. 281–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Bento, N. D. Palmer, M. Zhong et al., “Heterogeneity in gene loci associated with type 2 diabetes on human chromosome 20q13.1,” Genomics, vol. 92, no. 4, pp. 226–234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. V. P. Bilan, E. M. Salah, S. Bastacky et al., “Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats,” Journal of Endocrinology, vol. 210, no. 3, pp. 293–308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. P. Tofovic and E. K. Jackson, “Rat models of the metabolic syndrome,” Methods in Molecular Medicine, vol. 86, pp. 29–46, 2003. View at Google Scholar · View at Scopus
  21. S. Prabhakar, J. Starnes, S. Shi, B. Lonis, and R. Tran, “Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2945–2952, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. D. S. Tofovic, V. P. Bilan, and E. K. Jackson, “Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome,” Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 7, pp. 689–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Dominguez, P. Wu, J. W. Hawes et al., “Renal injury: similarities and differences in male and female rats with the metabolic syndrome,” Kidney International, vol. 69, no. 11, pp. 1969–1976, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. P. Tofovic, H. Kusaka, C. K. Kost Jr., and S. Bastacky, “Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats,” Renal Failure, vol. 22, no. 4, pp. 387–406, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. P. B. Mortensen, N. Gregersen, S. Kolvraa, and E. Christensen, “The occurrence of C6–C10 dicarboxylic acids in urine from patients and rats treated with dipropylacetate,” Biochemical Medicine, vol. 24, no. 2, pp. 153–161, 1980. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Sharma, B. Karl, A. V. Mathew et al., “Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1901–1912, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. C. D. Cropp, T. Komori, J. E. Shima et al., “Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP,” Molecular Pharmacology, vol. 73, no. 4, pp. 1151–1158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E.-I. Lepist, X. Zhang, J. Hao et al., “Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat,” Kidney International, vol. 86, pp. 350–357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Takizawa, I. Takasaki, H. Shionoiri, and M. Ishii, “Progression of glomerulosclerosis, renal hypertrophy, and an increased expression of fibronectin in the renal cortex associated with aging and salt-induced hypertension in Dahl salt-sensitive rats,” Life Sciences, vol. 61, no. 16, pp. 1553–1558, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. L. H. Chen and P. S. Leung, “Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus,” Diabetes, Obesity and Metabolism, vol. 15, no. 5, pp. 392–402, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. N. M. Tabatabai, M. Sharma, S. S. Blumenthal, and D. H. Petering, “Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats,” Diabetes Research and Clinical Practice, vol. 83, no. 1, pp. e27–e30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Kimura, S. Masuda, Y. Tanihara et al., “Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1,” Drug metabolism and Pharmacokinetics, vol. 20, no. 5, pp. 379–386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. T. Nowicki, L. M. Aleksunes, S. P. Sawant, A. V. Dnyanmote, H. M. Mehendale, and J. E. Manautou, “Renal and hepatic transporter expression in type 2 diabetic rats,” Drug Metabolism Letters, vol. 2, no. 1, pp. 11–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Lu and C. Klaassen, “Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats,” Drug Metabolism and Disposition, vol. 36, no. 1, pp. 16–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Jin, R. Kikuchi, T. Saji, H. Kusuhara, and Y. Sugiyama, “Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 α/β and DNA methylation,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 3, pp. 648–655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Kekuda, P. Saha, and U. Sundaram, “Role of Sp1 and HNF1 transcription factors in SGLT1 regulation during chronic intestinal inflammation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 294, no. 6, pp. G1354–G1361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. V. P. O'Brien, K. Bokelmann, J. Ramírez et al., “Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 Gene,” The Journal of Pharmacology and Experimental Therapeutics, vol. 347, no. 1, pp. 181–192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Pontoglio, D. Prié, C. Cheret et al., “HNF1alpha controls renal glucose reabsorption in mouse and man,” EMBO Reports, vol. 1, no. 4, pp. 359–365, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. T. F. Gallegos, G. Martovetsky, V. Kouznetsova, K. T. Bush, and S. K. Nigam, “Organic anion and cation slc22 “drug” transporter (oat1, oat3, and oct1) regulation during development and maturation of the kidney proximal tubule,” PLoS ONE, vol. 7, no. 7, Article ID e40796, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Niehof and J. Borlak, “HNF4α and the Ca-channel TRPC1 are novel disease candidate genes in diabetic nephropathy,” Diabetes, vol. 57, no. 4, pp. 1069–1077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Ljubojevic, D. Balen, D. Breljak et al., “Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones,” American Journal of Physiology—Renal Physiology, vol. 292, no. 1, pp. F361–F372, 2007. View at Publisher · View at Google Scholar
  43. D. C. Brater, “Diuretic therapy,” The New England Journal of Medicine, vol. 339, no. 6, pp. 387–395, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. K. M. Ho and B. M. Power, “Benefits and risks of furosemide in acute kidney injury,” Anaesthesia, vol. 65, no. 3, pp. 283–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. C. G. Musso, M. Navarro, C. Mombelli et al., “Furosemide test in stage III-chronic kidney disease and kidney transplant patients on tacrolimus,” International Urology and Nephrology, vol. 45, no. 5, pp. 1471–1474, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Vasavada, C. Saha, and R. Agarwal, “A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease,” Kidney International, vol. 64, no. 2, pp. 632–640, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Hasannejad, M. Takeda, K. Taki et al., “Interactions of human organic anion transporters with diuretics,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 3, pp. 1021–1029, 2004. View at Publisher · View at Google Scholar · View at Scopus